Finance

Lists
Q3 2026 earnings • released • EPS miss -62.19% • Revenue miss -90.66%
See results
MCRB:NASDAQ
Seres Therapeutics Inc
$1.98
-5.26%
(-0.11) 1D
$2.06
+4.04% (+0.080)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MCRB...
Open
$2.13
High
$2.26
Low
$1.96
Mkt. cap
19.68M
Avg. vol.
80.27K
Volume
82.28K
52-wk high
$29.98
52-wk low
$1.68
EPS
-$2.33
Beta
0.44
Shares outstanding
10.20M
No. of employees
66
Open
$2.13
High
$2.26
Low
$1.96
Mkt. cap
19.68M
Avg. vol.
80.27K
Volume
82.28K
52-wk high
$29.98
52-wk low
$1.68
EPS
-$2.33
Beta
0.44
Shares outstanding
10.20M
No. of employees
66
News stories
From web sources and news partners
About Seres Therapeutics Inc
CEOEric Shaff
Employees66
Founded2010
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteserestherapeutics.com
Analyst ratings
Based on 2 analysts giving stock ratings to MCRB in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MCRB in the last 3 months.
Highest
Current $1.98
$22.00 (+1,011.11%)
Average
$17.00 (+758.59%)
Lowest
$12.00 (+506.06%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
$22.00
+1,011.1%
11/04/2026
Matthew Keller
H.C. Wainwright
Buy
Reiterated
$12.00
+506.1%
11/04/2026
Edward Tenthoff
Piper Sandler
Hold
Maintained
$20.00
+910.1%
02/13/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
11/05/2025
Last report
Nov 4, 2026
Fiscal period
Q3 2026
-$1.63 / -$1.00
-62.19%miss
Revenue / Est. (USD)
593.00K / 6.35M
-90.66%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
438.00K
358.00K
736.00K
593.00K
Cost of goods sold
12.28M
13.20M
9.14M
5.59M
Cost of revenue
12.28M
13.20M
9.14M
5.59M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.54M
8.07M
7.06M
5.45M
Operating expense
7.54M
8.07M
7.06M
5.45M
Total operating expenses
19.82M
21.26M
16.20M
11.04M
Operating income
-19.38M
-20.91M
-15.47M
-10.45M
Other non operating income
2.33M
669.00K
673.00K
-280.00K
EBT including unusual items
-15.34M
-19.91M
4.58M
-16.29M
EBT excluding unusual items
-16.60M
-19.91M
-14.61M
-10.58M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.34M
-19.91M
4.58M
-16.29M
Net profit margin
-3,501.14%
-5,562.29%
622.42%
-2,746.37%
Earnings per share
-1.76
-2.08
1.07
-1.63
Interest and investment income
445.00K
325.00K
181.00K
146.00K
Interest expense
-
-
-
-
Net interest expenses
445.00K
325.00K
181.00K
146.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.42M
-20.13M
-14.80M
-9.78M
Gain or loss from assets sale
-192.00K
-
139.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps